COMPASS Pathways, a mental health treatment firm, gained the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit health-related researcher, acquired the designation to continue its testing of psilocybin to be a treatment for big depressive disorder.Usage of psychedelics is on the